X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
beacopp (120) 120
index medicus (91) 91
chemotherapy (89) 89
humans (88) 88
oncology (86) 86
abvd (83) 83
disease (70) 70
hodgkin disease - drug therapy (70) 70
female (59) 59
male (58) 58
antineoplastic combined chemotherapy protocols - therapeutic use (54) 54
adult (50) 50
middle aged (48) 48
hematology (47) 47
adolescent (44) 44
hodgkin lymphoma (44) 44
treatment outcome (41) 41
hodgkin disease - pathology (39) 39
trial (37) 37
lymphomas (32) 32
neoplasm staging (32) 32
prognosis (30) 30
hodgkin's lymphoma (28) 28
young adult (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (27) 27
bleomycin - administration & dosage (26) 26
doxorubicin - administration & dosage (26) 26
antineoplastic combined chemotherapy protocols - administration & dosage (25) 25
hodgkin's disease (25) 25
positron-emission-tomography (25) 25
radiotherapy (25) 25
cyclophosphamide - administration & dosage (23) 23
etoposide - administration & dosage (23) 23
hodgkin disease - mortality (23) 23
procarbazine - administration & dosage (23) 23
vincristine - administration & dosage (23) 23
bleomycin - therapeutic use (22) 22
doxorubicin - therapeutic use (22) 22
prednisone - administration & dosage (22) 22
regimen (22) 22
aged (21) 21
bleomycin - adverse effects (21) 21
cancer (21) 21
doxorubicin - adverse effects (21) 21
bleomycin (19) 19
lymphoma (19) 19
therapy (19) 19
disease-free survival (18) 18
etoposide (18) 18
retrospective studies (18) 18
vinblastine - administration & dosage (18) 18
vincristine - therapeutic use (18) 18
cyclophosphamide - therapeutic use (17) 17
dacarbazine - administration & dosage (17) 17
etoposide - therapeutic use (17) 17
hodgkin disease - radiotherapy (17) 17
hodgkin disease - therapy (17) 17
prednisone - therapeutic use (17) 17
procarbazine - therapeutic use (17) 17
care and treatment (16) 16
cyclophosphamide - adverse effects (16) 16
etoposide - adverse effects (16) 16
prednisone - adverse effects (16) 16
procarbazine - adverse effects (16) 16
survival analysis (16) 16
vincristine - adverse effects (16) 16
dacarbazine - adverse effects (15) 15
hodgkin disease - diagnostic imaging (15) 15
medicine & public health (15) 15
mopp (15) 15
vinblastine - adverse effects (15) 15
brentuximab vedotin (14) 14
combined modality therapy (14) 14
cyclophosphamide (14) 14
kaplan-meier estimate (14) 14
risk factors (14) 14
survival (14) 14
dacarbazine - therapeutic use (13) 13
follow-up studies (13) 13
open-label (13) 13
prognostic score (13) 13
standard (13) 13
vinblastine - therapeutic use (13) 13
fdg-pet (12) 12
hodgkin disease - diagnosis (12) 12
pet (12) 12
escalated beacopp (11) 11
prednisone (11) 11
toxicity (11) 11
anthracyclines (10) 10
doxorubicin (10) 10
positron-emission tomography (10) 10
prospective studies (10) 10
vinblastine (10) 10
international prognostic score (9) 9
overall survival (9) 9
positron emission tomography (9) 9
procarbazine (9) 9
risk assessment (9) 9
stanford-v (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 08/2013, Volume 31, Issue 24, pp. 3046 - 3046
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 09/2013, Volume 14, Issue 10, pp. 911 - 912
Journal Article
Oncotarget, ISSN 1949-2553, 07/2019, Volume 10, Issue 43, pp. 4354 - 4355
Journal Article
Der Onkologe, ISSN 0947-8965, 4/2018, Volume 24, Issue 4, pp. 315 - 321
Das Gesamtüberleben von Patienten mit fortgeschrittenem Hodgkin-Lymphom (HL), die mit dem aktuellen Standard der Deutschen Hodgkin Studiengruppe (DHSG),... 
Targeted BEACOPP | BEACOPP escalated | BEACOPP eskaliert | Gesamtüberleben | Medicine & Public Health | Oncology | German Hodgkin Study Group | Deutsche Hodgkin Studiengruppe | Brentuximab Vedotin | Overall survival
Journal Article
Onkologe, ISSN 0947-8965, 04/2018, Volume 24, Issue 4, pp. 315 - 321
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue 21, pp. 2273 - 2279
The HD18 study for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) used positron emission tomography (PET) after 2 cycles (PET-2) of... 
TRIAL | SURVIVAL | ABVD | POSITRON-EMISSION-TOMOGRAPHY | BEACOPP | RESPONSE-ADAPTED THERAPY | OPEN-LABEL | SCAN | RADIOTHERAPY | HEMATOLOGY | CHEMOTHERAPY
Journal Article
Acta Haematologica Polonica, ISSN 0001-5814, 2014, Volume 45, Issue 2, pp. 137 - 142
Hodgkin lymphoma is a disease with good prognosis. Using modern combined modalities, such as chemo- and radiotherapy, up to 90% of patients with limited-stage... 
Abvd | Beacopp | Hodgkin lymphoma
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2016, Volume 34, Issue 17, pp. 2020 - 2027
Journal Article
ONKOLOGE, ISSN 0947-8965, 05/2014, Volume 20, Issue 5, pp. 457 - 457
With the current standard of care of the German Hodgkin Study Group (GHSG) consisting of 6 cycles of the BEACOPP(escalated) regimen and radiotherapy of... 
Targeted BEACOPP | Brentuximab vedotin | BEACOPP | BEACOPP(escalated) | CHEMOTHERAPY | FERTILITY | TRIAL | ABVD | ONCOLOGY | SGN-35 | Overall survival | SURVIVORS | Hodgkin's lymphoma | GONADAL-FUNCTION
Journal Article
Archives of Biochemistry and Biophysics, ISSN 0003-9861, 06/2018, Volume 648, pp. 12 - 19
Curcumin reduces Hodgkin's lymphoma (HL) cell growth in vitro, but its unfavorable pharmacokinetics highlight the need for novel in vivo delivery systems.... 
Curcumin | SLN | TPGS | Hodgkin's lymphoma | BIOCHEMISTRY & MOLECULAR BIOLOGY | BEACOPP | DOXORUBICIN | NON-STEALTH | CHEMOTHERAPY | LUNG-CANCER | ABVD | IN-VITRO | THERAPY | BIOPHYSICS | PHARMACOKINETICS | SULINDAC | Index Medicus
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 06/2015, Volume 26, Issue 6, pp. 1170 - 1174
Background: Combination chemotherapy ABVD (doxorubicin, bleomycin, vinblastine and dacarabazine) cures similar to 70% of patients with advanced Hodgkin's... 
interim PET-CT scan | BEACOPP | CONSENSUS | INTERNATIONAL PROGNOSTIC SCORE | CHEMOTHERAPY | TRIAL | ABVD | escalated BEACOPP | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | Deauville score | DISEASE | INTERPRETATION CRITERIA | response-adapted therapy | Hodgkin's lymphoma | Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Predictive Value of Tests | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Positron-Emission Tomography | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Multimodal Imaging | Time Factors | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Female | Child | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Risk Factors | Kaplan-Meier Estimate | Etoposide - administration & dosage | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Disease Progression | India | Disease-Free Survival | Procarbazine - adverse effects | Adolescent | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus
Journal Article
ONKOLOGE, ISSN 0947-8965, 04/2018, Volume 24, Issue 4, pp. 315 - 321
With the current standard of care of the German Hodgkin Study Group (DHSG) consisting of interim positron emission tomography (PET)-guided administration of... 
Targeted BEACOPP | Brentuximab vedotin | German Hodgkin Study Group | OPEN-LABEL | BEACOPP(escalated) | INTERNATIONAL PROGNOSTIC SCORE | TRIAL | ABVD | POSITRON-EMISSION-TOMOGRAPHY | THERAPY | ONCOLOGY | DISEASE | INTERGROUP | Overall survival | SURVIVORS
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.